307 related articles for article (PubMed ID: 33080858)
21. MicroRNAs in breast cancer pathogenesis.
Götte M
Minerva Ginecol; 2010 Dec; 62(6):559-71. PubMed ID: 21079577
[TBL] [Abstract][Full Text] [Related]
22. Tree-based machine learning algorithms identified minimal set of miRNA biomarkers for breast cancer diagnosis and molecular subtyping.
Sherafatian M
Gene; 2018 Nov; 677():111-118. PubMed ID: 30055304
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
24. MicroRNAs in Breast Cancer: Diagnostic and Therapeutic Potential.
Asiaf A; Ahmad ST; Arjumand W; Zargar MA
Methods Mol Biol; 2018; 1699():23-43. PubMed ID: 29086366
[TBL] [Abstract][Full Text] [Related]
25. Identification of prognostic biomarkers for breast cancer based on miRNA and mRNA co-expression network.
Yao Y; Liu R; Gao C; Zhang T; Qi L; Liu G; Zhang W; Wang X; Li J; Li J; Sun C
J Cell Biochem; 2019 Sep; 120(9):15378-15388. PubMed ID: 31037764
[TBL] [Abstract][Full Text] [Related]
26. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.
Liu R; Guo CX; Zhou HH
Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514
[TBL] [Abstract][Full Text] [Related]
27. The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment.
Davey MG; Davies M; Lowery AJ; Miller N; Kerin MJ
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361056
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
Andorfer CA; Necela BM; Thompson EA; Perez EA
Trends Mol Med; 2011 Jun; 17(6):313-9. PubMed ID: 21376668
[TBL] [Abstract][Full Text] [Related]
29. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
30. Clinical aspects of circulating miRNA-335 in breast cancer patients: A prospective study.
Swellam M; Mahmoud MS; Hashim M; Hassan NM; Sobeih ME; Nageeb AM
J Cell Biochem; 2019 Jun; 120(6):8975-8982. PubMed ID: 30506730
[TBL] [Abstract][Full Text] [Related]
31. The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer.
Bertoli G; Cava C; Castiglioni I
Scand J Clin Lab Invest Suppl; 2016; 245():S34-9. PubMed ID: 27435502
[TBL] [Abstract][Full Text] [Related]
32. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
33. Prioritizing breast cancer subtype related miRNAs using miRNA-mRNA dysregulated relationships extracted from their dual expression profiling.
Hua L; Zhou P; Li L; Liu H; Yang Z
J Theor Biol; 2013 Aug; 331():1-11. PubMed ID: 23619378
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
35. Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer.
Suman S; Basak T; Gupta P; Mishra S; Kumar V; Sengupta S; Shukla Y
J Proteomics; 2016 Oct; 148():183-93. PubMed ID: 27498393
[TBL] [Abstract][Full Text] [Related]
36. The impact of microRNAs on the resistance of breast cancer subtypes to chemotherapy.
Ebrahimi A; Bakhshaei Shahrebabaki P; Fouladi H; Mansoori Derakhshan S
Pathol Res Pract; 2023 Sep; 249():154702. PubMed ID: 37562283
[TBL] [Abstract][Full Text] [Related]
37. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
[TBL] [Abstract][Full Text] [Related]
38.
Gallivanone F; Cava C; Corsi F; Bertoli G; Castiglioni I
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31756987
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
40. miRNA profile of luminal breast cancer subtyptes in Slovak women.
Danková Z; Grendár M; Dvorská D; Braný D; Stastny I; Bobrovská M; Balhárek T; Zubor P
Ceska Gynekol; 2020; 85(3):174-180. PubMed ID: 33562968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
